Cohance Lifesciences Limited (BOM:543064)

Market Cap	115.80B -60.9%
Revenue (ttm)	10.79B +2.9%
Net Income	606.40M -78.3%
EPS	2.35 -78.5%
Shares Out	n/a
PE Ratio	190.97
Forward PE	32.26
Dividend	n/a
Ex-Dividend Date	n/a

Volume	72,938
Average Volume	67,882
Open	304.55
Previous Close	305.95
Day's Range	296.40 - 308.80
52-Week Range	267.85 - 1,246.85
Beta	n/a
RSI	43.72
Earnings Date	May 29, 2026

About Cohance Lifesciences

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluores...

• Industry: Pharmaceutical Preparations
• Founded: 1989
• Employees: 1,212
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543064

Financial Performance

In fiscal year 2025, Cohance Lifesciences's revenue was 11.98 billion, an increase of 13.91% compared to the previous year's 10.51 billion. Earnings were 2.68 billion, a decrease of -10.79%.